Use of apraclonidine to reduce acute intraocular pressure rise following Q-switched Nd:YAG laser iridotomy

Ophthalmic Surg. 1989 Jan;20(1):49-52.

Abstract

We evaluated the effectiveness of topical apraclonidine (ALO 2145, p-amino clonidine hydrochloride) in suppressing an acute postoperative intraocular pressure (IOP) rise following Nd:YAG laser iridotomy. Fifty-eight eyes (45 patients) with chronic primary angle-closure glaucoma underwent Q-switched Nd:YAG laser iridotomy. Twenty-nine eyes followed prospectively underwent Nd:YAG laser iridotomy following the topical administration of 0.5% apraclonidine prior to and immediately following the procedure. A retrospective control group of 29 eyes underwent Nd:YAG laser iridotomy without topical apraclonidine. Only one eye (3.4%) treated with apraclonidine experienced an IOP rise greater than 10 mm Hg over baseline, while five among 29 untreated eyes (17.2%) developed an IOP rise greater than 10 mm Hg.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Clonidine / analogs & derivatives*
  • Clonidine / therapeutic use
  • Female
  • Glaucoma / surgery
  • Gonioscopy
  • Humans
  • Intraocular Pressure / drug effects
  • Iris / surgery*
  • Laser Therapy / adverse effects*
  • Male
  • Ocular Hypertension / drug therapy*
  • Ocular Hypertension / etiology
  • Postoperative Complications
  • Prospective Studies
  • Time Factors

Substances

  • apraclonidine
  • Clonidine